FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151754893> ?p ?o ?g. }

• W2151754893 endingPage "551" @default.
• W2151754893 startingPage "548" @default.
• W2151754893 abstract "HomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 32, No. 3Restoring Elastin With MicroRNA-29 Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBRestoring Elastin With MicroRNA-29 Xiu Rong Dong and Mark W. Majesky Xiu Rong DongXiu Rong Dong From the Seattle Children's Research Institute (X.R.D.), Department of Pediatrics (M.W.M.), Department of Pathology (M.W.M.), and Institute of Stem Cell & Regenerative Medicine (M.W.M.), University of Washington, Seattle, WA. Search for more papers by this author and Mark W. MajeskyMark W. Majesky From the Seattle Children's Research Institute (X.R.D.), Department of Pediatrics (M.W.M.), Department of Pathology (M.W.M.), and Institute of Stem Cell & Regenerative Medicine (M.W.M.), University of Washington, Seattle, WA. Search for more papers by this author Originally published1 Mar 2012https://doi.org/10.1161/ATVBAHA.111.242412Arteriosclerosis, Thrombosis, and Vascular Biology. 2012;32:548–551Elastin (Eln) is a highly distensible protein that enables tissues such as lung, skin, and large arteries to expand and return to their original shape.1 Tropoelastin is encoded by a single copy gene that is highly expressed in utero and then strongly downregulated after birth.2,3 Only low maintenance levels of tropoelastin mRNA are found in most elastic tissues in adults.3,4 Repair of severe injuries, such as third-degree burns, produces tissue that is often heavily scarred and severely limited in flexibility, range of motion, and tissue function.5 Similar scarring is seen after prolonged cancer radiation therapy, in sun-damaged skin,6 and in systemic sclerosis.7,8 In the vasculature, Eln haploinsufficient phenotypes include narrowing (stenosis) of the ascending aorta in the perinatal period and hypertension later in life. Overdistention injury of arteries after balloon catheter-based therapies activates repair responses in the adventitia that closely resemble skin wound contractures and can drive lumen narrowing in restenosis.9 These aberrant conditions have in common the production of a collagen-rich extracellular matrix (ECM) that is deficient in elastic fibers. A major cause of the deficiency in elastic fiber production is the failure to upregulate tropoelastin gene expression in postnatal tissues subject to the injuries described above. An article by Zhang et al in this issue of Arteriosclerosis, Thrombosis, and Vascular Biology describes a novel approach to increase Eln production that may change clinical outcomes in conditions such as those described above.10See accompanying article on page 756Eln and the Elastic FiberThe elastic fiber is built up by a stepwise addition of tropoelastin monomers on a microfibrillar scaffold (Figure). The core of a microfibril is composed of the glycoprotein fibrillin.11 Fibrillin is deposited in the extracellular space and once there interacts with a group of microfibril-associated proteins, including fibulins, emilins, microfiber-associated glycoproteins, and latent transforming growth factor-β binding proteins.11,12 Cross-linking of tropoelastin monomers is carried out by the lysyl oxidases, a family of copper-dependent amine oxidases.13 Once assembled and extensively cross-linked, elastic fibers in tissues are very stable, with turnover times measured in decades.3,12 The stability of the elastic fiber may be the reason for the very low levels of tropoelastin gene expression found in most adult tissues.3 In mice, loss of function mutations in Eln produce dramatic developmental phenotypes, particularly in large elastic arteries.14,15 Eln-null mice (Eln−/−) die within a few days after birth from overproliferation of vascular smooth muscle cells (SMCs) that occludes the aortic lumen.14 These mice develop elongated, tortuous arteries with stiff walls that are physiologically noncompliant.12,14 By contrast, Eln+/− mice are viable, and their arteries have thinner walls, smaller lumens, and more layers of SMCs between attenuated elastic lamellae than wild-type arteries.12,15Eln+/− mice develop higher systemic blood pressures, leading to increased circumferential wall stress, but because of the increased number of elastic lamellae, the tension per lamellar unit is the same as in wild-type mice.12,15Download figureDownload PowerPointFigure. Tropoelastin (TE) production is under control of microRNA (miR)-29. TE mRNA contains seed sequences in the 3′-untranslated region (UTR) that are recognized by miR-29. Binding of miR-29 to TE mRNA inhibits TE synthesis. miR-29 inhibitors block this step and thereby increase TE protein production. Once made, TE protein is secreted into the extracellular matrix of elastic tissues such as lung, skin, and artery wall. TE protein then interacts with elements of the elastic fiber scaffold composed of fibrillin, fibulin, emilin, microfiber-associated glycoproteins (MGAPs), lysyl oxidases (LOXs), and latent transforming growth factor-β binding proteins (LTBPs). The elastic fiber has unique biomechanical properties that enable tissues to stretch and return to their original shapes.1,11,12 Deficiencies in TE production can produce or exacerbate aneurysms, scars associated with severe burns, tissue fibrosis or systemic sclerosis, and loss of tissue function associated with emphysema and chronic obstructive pulmonary disease. Therapeutic approaches using miR-29 inhibitors may increase TE protein production and prove beneficial for these and related conditions.Human Phenotypes Associated With ELN HaploinsufficiencyWilliams-Beuren syndrome (WBS) is a disorder caused by a heterozygous microdeletion of 1.5 Mbp of DNA from chromosome 7q11.23.16 Patients with WBS exhibit a characteristic spectrum of cognitive and cardiovascular disorders, among which are stenoses of elastic arteries and hypertension.16 Although the chromosome 7 microdeletion involves 26 to 28 genes, it is the loss of 1 copy of the ELN gene that is the major contributor to the cardiovascular phenotypes in WBS individuals. The principal features of WBS arteries are an increase in wall thickness, an increase in the number of layers of SMCs and ELN, and a focal narrowing (stenosis) of elastic arteries particularly of the ascending aorta. Supravalvular aortic stenosis (SVAS) is an autosomal dominant heterozygous disruption limited to the ELN gene only, either by point mutation, translocation, or deletion.16,17 Patients with SVAS do not exhibit the cognitive, endocrine, and metabolic phenotypes common to WBS. However, SVAS patients do demonstrate considerable overlap with WBS patients in elastic artery structural defects and excessive proliferation of arterial SMCs.18 Collectively, the vascular defects observed in SVAS and WBS are called ELN arteriopathies and are conditions resulting from ELN haploinsufficiency.The MicroRNA-29 Family: Expression and FunctionMicroRNAs (miRNAs) are a class of ≈22-nucleotide noncoding small RNAs that play essential roles in regulating gene expression by posttranscriptional mechanisms.19 miRNAs have been shown to play important roles in cardiovascular development, physiology, and disease.20–22 The microRNA-29 (miR-29) family consists of 3 members encoded by 2 genomic bicistronic clusters.23 miR-29a and miR-29b1 are coexpressed from one cluster, and miR-29b2 and miR-29c are coexpressed from the other cluster. All miR-29 family members are widely expressed, and expression levels gradually increase with age. miR-29 family members share a conserved seed region, and their predicted targets are enriched in ECM proteins and ECM proteases, suggesting physiological roles in morphogenesis and tissue remodeling and pathological roles in aortic aneurysms24 and Marfan syndrome.25 Specific ECM targets for miR-29 family members include tropoelastin, collagen type I (α1) (COL1A1), collagen type I (α2) (COL1A2), collagen type III (α1) (COL3A1), and fibrillin-1.23Restoring ELN Expression With miR-29 AntagonistsUsing human dermal fibroblasts and vascular SMCs, Zhang et al showed that overexpression of miR-29a/b/c mimics repressed, whereas miR-29 inhibitors increased, ELN mRNA and protein levels in vitro.10 miRNAs are versatile regulators of gene expression and individual miRNAs are known to target multiple gene products.19,20,22 In the case of miR-29, conserved seed sequences are found not only in tropoelastin but also in COL1A1, COL3A1, and VEGF-A, among others. Indeed, Zhang et al found that overexpression of miR-29 decreased the activity of luciferase reporter plasmids containing 3′-untranslated regions from COL1A1, COL3A1, and VEGF-A. Moreover, incubation of human vascular SMCs in vitro for 15 hours in the presence of miR-29a inhibitor increased the levels of tropoelastin mRNA by 5-fold yet had little or no effect on COL1A1, COL3A1, fibrillin1, fibrillin2, fibrillin4, emilin1, lysyl oxidase (LOX), LOXL1, or LOXL2 gene expression. The specificity of this response is curious given the inhibition of COL1A1 and COL3A1 3′-untranslated region-luciferase reporters, and previous reports of miR29 inhibitor increasing levels of COL1A1 and COL3A1 in the heart.23Of particular interest, the authors then extended the study to include pulmonary artery SMCs obtained from an SVAS patient with an insertion in exon 9 of the ELN gene that causes a frameshift mutation resulting in a premature stop codon in exon 10. This mutation does not alter the level of miR-29 expression by these cells but results in low levels of full-length tropoelastin mRNA arising from 1 intact allele. Transfection of SVAS-SMCs with an miR-29a inhibitor increased expression levels of tropoelastin mRNA (3.5-fold) with corresponding increases in amounts of tropoelastin protein secreted into the culture medium or associated with the cell surface. Similar experiments were carried out on dermal fibroblasts obtained from 2 patients with WBS with confirmed haplodeficiency for ELN expression. Treatment of WBS cells with miR-29 inhibitor also increased levels of tropoelastin mRNA and protein secreted into conditioned medium.Although these in vitro results are promising, the functional form of ELN is not the secreted monomer but the heavily cross-linked polymer of ELN incorporated onto a microfiber scaffold in the ECM.11,12 To address the important question of whether increasing tropoelastin expression per se would result in functional increases in elastic fiber content and distensibility of the ECM, the authors turned to bioengineered vessels. Polyglycolic acid scaffolds seeded with human vascular SMCs were grown in a bioreactor for 6 weeks with or without miR-29a inhibitor and then examined by biochemical analysis, electron microscopy, and biaxial mechanical stress tests. In the absence of miR-29a inhibitor, there was little evidence of cross-linked elastic fibers in the ECM and only low levels of cell-associated ELN protein detectable by Western blots. By contrast, after incubation for 6 weeks in the presence of miR-29a inhibitor, islands of cross-linked ELN appeared in the ECM that significantly increased the distensibility of these polyglycolic acid bioengineered vessels at low pressures.10Remaining Questions Going ForwardThe results described by Zhang et al10 raise the optimistic possibility that miR-29 inhibitor therapy may offer hope to individuals living with ELN haploinsufficient phenotypes where loss of distensibility in arteries, lungs, skin, and other tissues affects overall health and quality of life. However, a number of questions will need to be addressed in future studies to better evaluate this exciting possibility. A major concern with moving forward with miR-29 antagonists to raise ELN production would be inadvertent stimulation of tissue fibrosis in individuals with preexisting conditions. Reducing the functional levels of miR-29 would be predicted to derepress expression of various collagens and produce a profibrotic phenotype. Reductions in miR-29 have already been implicated in fibrosis in liver,26 lung,27 kidney,28 and heart.23In a previous study, miR29 antagonists produced predicted increases in collagen levels but had no effect on Eln expression in the border zone of infarcted myocardium.23 These results may point to additional, possibly tissue-specific levels of regulation of miR-29 function in vivo.It still remains unclear whether increasing the synthesis and secretion of tropoelastin per se will prove to be sufficient for assembling a complex elastic fiber and incorporating that into the ECM in such a way that it will improve overall tissue flexibility, distensibility, and function (Figure). The bioengineered vessel studied by Zhang et al10 is producing an ECM de novo, whereas perinatal and adult tissues have already formed a complex ECM. Some measure of protease-dependent ECM turnover may be a prerequisite for miR29-based therapies to be successful.Likewise, WBS and SVAS patients typically present with symptoms after the disease has progressed to the point of clinical significance. Would increasing ELN expression in the setting of established disease be a sufficient stimulus to repair the existing tissue structure and to restore tissue function?Like all miRNAs, miR-29 has multiple mRNA targets that may present concerns for potential side effects (off-target effects). For example, other predicted targets for miR-29 include matrix metalloproteinase-2, platelet-derived growth factor receptor-β, and Krüppel-like factor-4 (TargetScanHuman, http://targetscan.org).In settings of chronic inflammation or repair of acute tissue injury where ECM degrading proteases are abundantly expressed, will sufficient amounts of newly produced tropoelastin escape degradation in the ECM to reach adequate levels to restore tissue function?Finally, it will be necessary to deliver sufficient amounts of miR29 inhibitor to the affected tissue to be an effective therapy. For internal organs, including lung and elastic arteries, that may present a challenge.SummaryThe effectiveness of miR-29 antagonists to significantly increase the production of tropoelastin in cells from individuals with haploinsufficient phenotypes for ELN suggests a promising way forward to improve the clinical picture for these patients. The beauty of miRNAs as biological regulators is they simultaneously target multiple mRNAs and thereby act to integrate single biological inputs into coordinated changes in expression of multiple gene targets to regulate complex cell phenotypes such as migration, differentiation, or metabolism. Therein lies a set of potential complications that will have to be sorted out by further studies to fully evaluate the exciting promise of the results reported by Zhang et al.10Sources of FundingThe authors were supported by National Institutes of Health Grants HL-93594 and HL-19242 and by the Seattle Children's Research Institute (Seattle, WA).DisclosuresNone.FootnotesCorrespondence to Mark W. Majesky, PhD, Seattle Children's Research Institute, University of Washington, 1900 Ninth Ave, M/S C9S-5, Seattle, WA 98101. E-mail mwm84@uw.eduReferences1. Baldock C, Oberhouser AF, Ma L, Lammie D, Siegler V, Mithieux SM, Tu Y, Chow JY, Suleman F, Malfois M, Rogers S, Guo L, Irving TC, Wess TJ, Weiss AS. Shape of tropoelastin, the highly distensible protein that controls human tissue elasticity. Proc Natl Acad Sci U S A. 2011; 108:4322–4327. CrossrefMedlineGoogle Scholar2. Bashir MM, Indik Z, Yeh H, Omstein-Goldstein N, Rosenbloom JC, Abrams W, Fazio M, Uitto J, Rosenbloom J. Characterization of the complete human elastin gene: delineation of unusual features in the 5′-flanking region. J Biol Chem. 1989; 264:8887–8891. CrossrefMedlineGoogle Scholar3. Davis EC. Stability of elastin in the developing mouse aorta: a quantitative radioautographic study. Histochemistry. 1993; 100:17–26. CrossrefMedlineGoogle Scholar4. Sherratt MJ. Tissue elasticity and the ageing elastic fibre. Age. 2009; 31:305–325. CrossrefMedlineGoogle Scholar5. Rnjak J, Wise SG, Mithieux SM, Weiss AS. Severe burn injuries and the role of elastin in the design of dermal substitutes. Tissue Eng Part B Rev. 2011; 17:81–91. CrossrefMedlineGoogle Scholar6. Suabe J., Serizawa A, Kajiwara H, Ohkido M, Tsutsumi Y. Degenerative processes of elastic fibers in sun-protected and sun-exposed skin: immunoelectron microscopic observation of elastin, fibrillin-1, amyloid P component, lysosyme and α1-antitrypsin. Pathol Int. 1999; 49:391–402. CrossrefMedlineGoogle Scholar7. Davis EC, Blattel SA, Mecham RP. Remodeling of elastic fiber components in scleroderma skin. Connect Tissue Res. 1999; 40:113–121. CrossrefMedlineGoogle Scholar8. Loeys BL, Gerber EE, Rieger-Johnson D, Iqbal S, Whiteman P, McConnell V, Chillakuri CR, Macaya D, Coucke PJ, De Paepe A, Judge DP, Wigley F, Davis EC, Mardon HJ, Handford P, Keene DR, Sakai L, Dietz HC. Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome. Sci Transl Med. 2010; 2:23ra20.CrossrefMedlineGoogle Scholar9. Ryan ST, Koteliansky VE, Gotwals PJ, Lindner V. Transforming growth factor-β-dependent events in vascular remodeling following arterial injury. J Vasc Res. 2002; 40:37–46. CrossrefGoogle Scholar10. Zhang P, Huang A, Ferruzzi J, Mecham RP, Starcher BC, Tellides G, Humphrey JD, Giordano FJ, Niklason LE, Sessa WC. Inhibition of microRNA-29 enhances elastin levels in cells haploinsufficient for elastin and in bioengineered vessels—brief report. Arterioscler Thromb Vasc Biol. 2012; 32:756–759. LinkGoogle Scholar11. Ramirez F, Dietz HC. Extracellular microfibrils in vertebrate development and disease processes. J Biol Chem. 2009; 284:14677–14681. CrossrefMedlineGoogle Scholar12. Wagenseil JE, Mecham RP. Vascular extracellular matrix and arterial mechanics. Physiol Rev. 2009; 89:957–989. CrossrefMedlineGoogle Scholar13. Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem. 2003; 88:660–672. CrossrefMedlineGoogle Scholar14. Li DY, Brooke B, Davis EC, Mecham RP, Sorensen LK, Boak BB, Eichwald E, Keating MT. Elastin is an essential determinant of arterial morphogenesis. Nature. 1998; 393:276–280. CrossrefMedlineGoogle Scholar15. Faury G, Pezet M, Knutsen RH, Boyle WA, Heximer SP, McLean SE, Minkes RK, Blumer KJ, Kovacs A, Kelly DP, Li DY, Starcher B, Mecham RP. Developmental adaptation of the mouse cardiovascular system to elastin haploinsufficiency. J Clin Invest. 2003; 112:1419–1428. CrossrefMedlineGoogle Scholar16. Pober BR, Johnson M, Urban Z. Mechanisms and treatment of cardiovascular disease in Williams-Beuren syndrome. J Clin Invest. 2008; 118:1606–1615. CrossrefMedlineGoogle Scholar17. Urban Z, Zhang J, Davis EC, Maeda GK, Kumar A, Stalker H, Belmont JH, Boyd CD, Wallace MR. Supravalvular aortic stenosis: genetic and molecular dissection of a complex mutation in the elastin gene. Hum Genet. 2001; 109:512–520. CrossrefMedlineGoogle Scholar18. Urban Z, Riazi S, Seidl TL, Katagira J, Smoot LB, Chitayat D, Boyd CD, Hinek A. Connection between elastin haploinsufficiency and increased cell proliferation in patients with supravalvular aortic stenosis and Williams-Beuren syndrome. Am J Hum Genet. 2002; 71:30–44. CrossrefMedlineGoogle Scholar19. Bartel D. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136:215–233. CrossrefMedlineGoogle Scholar20. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature. 2011; 409:336–342. CrossrefGoogle Scholar21. Ott CE, Grunhagen J, Jager M, Horbelt D, Schwill S, Kallenbach K, Guo G, Manke T, Knauss P, Mundlos S, Robinson PN. MicroRNAs differentially expressed in postnatal aortic development downregulate elastin via 3′UTR and coding-sequence binding sites. PLoS One. 2011; 6:e16250.CrossrefMedlineGoogle Scholar22. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 2007; 4:721–726. CrossrefMedlineGoogle Scholar23. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, Olson EN. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A. 2008; 105:13027–13032. CrossrefMedlineGoogle Scholar24. Boon RA, Seeger T, Heydt S, Fischer A, Hergenreider E, Horrevoets AJ, Vinciguerra M, Rosenthal N, Sciacca S, Pilato M, van Heijningen P, Essers J, Brandes RP, Zeiher AM, Dimmeler S. MicroRNA-29 in aortic dilation: implications for aneurysm formation. Circ Res. 2011; 109:1115–1119. LinkGoogle Scholar25. Merk DR, Chin JT, Dake BA, Maegdefessel L, Miller MO, Kimura N, Tsao PS, Iosef C, Berry GJ, Mohr FW, Spin JM, Alvira CM, Robbins RC, Fischbein MP. miR-29b participates in early aneurysm development in Marfan Syndrome. Circ Res. 2012; 110:312–324. LinkGoogle Scholar26. Kwiecinski M, Noetel A, Elfimova N, Trebicka J, Schievenbusch S, Strack I, Molnar L, von Brandenstein M, Tox U, Nischt R, Coutelle O, Dienes HP, Odenthal M. Hepatocyte growth factor (HGF) inhibits collagen I and IV synthesis in hepatic stellate cells by miRNA-29 induction. PLoS One. 2011; 6:e24568.CrossrefMedlineGoogle Scholar27. Cushing L, Kuang PP, Qian J, Shao F, Wu J, Little F, Thannickal VJ, Cardoso WV, Lu J. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011; 45:287–294. CrossrefMedlineGoogle Scholar28. Qin W, Chung C, Huang XR, Meng XM, Hui DS, Yu CS, Sung JJ, Lan HY. TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol. 2011; 22:1462–1474. CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Hill J, Eekhoff J, Brophy R and Lake S (2020) Elastic fibers in orthopedics: Form and function in tendons and ligaments, clinical implications, and future directions, Journal of Orthopaedic Research, 10.1002/jor.24695, 38:11, (2305-2317), Online publication date: 1-Nov-2020. Gong J, Zhou D, Jiang L, Qiu P, Milewicz D, Chen Y and Yang B (2020) In Vitro Lineage-Specific Differentiation of Vascular Smooth Muscle Cells in Response to SMAD3 Deficiency, Arteriosclerosis, Thrombosis, and Vascular Biology, 40:7, (1651-1663), Online publication date: 1-Jul-2020. Mithieux S and Weiss A (2017) Design of an elastin-layered dermal regeneration template, Acta Biomaterialia, 10.1016/j.actbio.2016.11.054, 52, (33-40), Online publication date: 1-Apr-2017. Joshi J and Kothapalli C (2016) Recent Approaches and Future Perspectives on Elastin Regeneration and Repair Elastic Fiber Matrices, 10.1201/b20266-10, (285-323), Online publication date: 19-May-2016. Klingberg F, Hinz B and White E (2012) The myofibroblast matrix: implications for tissue repair and fibrosis, The Journal of Pathology, 10.1002/path.4104, 229:2, (298-309), Online publication date: 1-Jan-2013. March 2012Vol 32, Issue 3 Advertisement Article InformationMetrics © 2012 American Heart Association, Inc.https://doi.org/10.1161/ATVBAHA.111.242412PMID: 22345590 Originally publishedMarch 1, 2012 Keywordsaneurysmsmorphogenesisextracellular matrixgene expressionPDF download Advertisement SubjectsDevelopmental BiologyGene Expression and RegulationSmooth Muscle Proliferation and Differentiation" @default.
• W2151754893 created "2016-06-24" @default.
• W2151754893 creator A5033878042 @default.
• W2151754893 creator A5073772138 @default.
• W2151754893 date "2012-03-01" @default.
• W2151754893 modified "2023-10-03" @default.
• W2151754893 title "Restoring Elastin With MicroRNA-29" @default.
• W2151754893 cites W1653019055 @default.
• W2151754893 cites W1653700630 @default.
• W2151754893 cites W1963906441 @default.
• W2151754893 cites W1964471997 @default.
• W2151754893 cites W1965895613 @default.
• W2151754893 cites W1972989638 @default.
• W2151754893 cites W1985268990 @default.
• W2151754893 cites W1994589849 @default.
• W2151754893 cites W1999191452 @default.
• W2151754893 cites W2003570106 @default.
• W2151754893 cites W2011368078 @default.
• W2151754893 cites W2019825630 @default.
• W2151754893 cites W2025309753 @default.
• W2151754893 cites W2064792916 @default.
• W2151754893 cites W2065502996 @default.
• W2151754893 cites W2100044667 @default.
• W2151754893 cites W2117768135 @default.
• W2151754893 cites W2120055234 @default.
• W2151754893 cites W2121317825 @default.
• W2151754893 cites W2125733524 @default.
• W2151754893 cites W2135580384 @default.
• W2151754893 cites W2140327368 @default.
• W2151754893 cites W2155290141 @default.
• W2151754893 cites W2158482287 @default.
• W2151754893 cites W2160390633 @default.
• W2151754893 cites W2162674813 @default.
• W2151754893 cites W2169754078 @default.
• W2151754893 cites W2171591131 @default.
• W2151754893 doi "https://doi.org/10.1161/atvbaha.111.242412" @default.
• W2151754893 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3390171" @default.
• W2151754893 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22345590" @default.
• W2151754893 hasPublicationYear "2012" @default.
• W2151754893 type Work @default.
• W2151754893 sameAs 2151754893 @default.
• W2151754893 citedByCount "8" @default.
• W2151754893 countsByYear W21517548932012 @default.
• W2151754893 countsByYear W21517548932014 @default.
• W2151754893 countsByYear W21517548932016 @default.
• W2151754893 countsByYear W21517548932017 @default.
• W2151754893 countsByYear W21517548932020 @default.
• W2151754893 countsByYear W21517548932023 @default.
• W2151754893 crossrefType "journal-article" @default.
• W2151754893 hasAuthorship W2151754893A5033878042 @default.
• W2151754893 hasAuthorship W2151754893A5073772138 @default.
• W2151754893 hasBestOaLocation W21517548931 @default.
• W2151754893 hasConcept C104317684 @default.
• W2151754893 hasConcept C145059251 @default.
• W2151754893 hasConcept C169760540 @default.
• W2151754893 hasConcept C2779869378 @default.
• W2151754893 hasConcept C41008148 @default.
• W2151754893 hasConcept C54355233 @default.
• W2151754893 hasConcept C70721500 @default.
• W2151754893 hasConcept C86803240 @default.
• W2151754893 hasConceptScore W2151754893C104317684 @default.
• W2151754893 hasConceptScore W2151754893C145059251 @default.
• W2151754893 hasConceptScore W2151754893C169760540 @default.
• W2151754893 hasConceptScore W2151754893C2779869378 @default.
• W2151754893 hasConceptScore W2151754893C41008148 @default.
• W2151754893 hasConceptScore W2151754893C54355233 @default.
• W2151754893 hasConceptScore W2151754893C70721500 @default.
• W2151754893 hasConceptScore W2151754893C86803240 @default.
• W2151754893 hasIssue "3" @default.
• W2151754893 hasLocation W21517548931 @default.
• W2151754893 hasLocation W21517548932 @default.
• W2151754893 hasLocation W21517548933 @default.
• W2151754893 hasLocation W21517548934 @default.
• W2151754893 hasOpenAccess W2151754893 @default.
• W2151754893 hasPrimaryLocation W21517548931 @default.
• W2151754893 hasRelatedWork W1966159854 @default.
• W2151754893 hasRelatedWork W1972785590 @default.
• W2151754893 hasRelatedWork W2046406569 @default.
• W2151754893 hasRelatedWork W2074821116 @default.
• W2151754893 hasRelatedWork W2118558281 @default.
• W2151754893 hasRelatedWork W2513408624 @default.
• W2151754893 hasRelatedWork W2594860815 @default.
• W2151754893 hasRelatedWork W3117169687 @default.
• W2151754893 hasRelatedWork W3136905963 @default.
• W2151754893 hasRelatedWork W3195428361 @default.
• W2151754893 hasVolume "32" @default.
• W2151754893 isParatext "false" @default.
• W2151754893 isRetracted "false" @default.
• W2151754893 magId "2151754893" @default.
• W2151754893 workType "article" @default.